The effect of human endothelial cell-derived proteoglycans on human smooth muscle cell growth

Cell Biology International

Volumn 21, Issue 3, 1997, Pages 181-189

  Whitelock, John ^a   Mitchell, Sue ^a   Underwood, P Anne ^a  

^a CSIRO   (Australia)

Author keywords

Endothelial cells; Human; Proteoglycans; Vascular smooth muscle

Indexed keywords

CHONDROITIN SULFATE; HEPARAN SULFATE; HEPARIN; PERLECAN; PLASMIN; PROTEOGLYCAN; SODIUM CHLORIDE;

ARTERY ENDOTHELIUM; ARTICLE; BASEMENT MEMBRANE; CELL ACTIVATION; CELL GROWTH; CELL PROLIFERATION; CONNECTIVE TISSUE; CONTROLLED STUDY; ENDOTHELIUM CELL; HUMAN; HUMAN CELL; SMOOTH MUSCLE; THROMBOCYTE;

EID: 0031105181     PISSN: 10656995     EISSN: None     Source Type: Journal    
DOI: 10.1006/cbir.1996.0125     Document Type: Article

References (39)

1. BAIRD A, LING M, 1987. Fibroblast growth factors are present in the extracellular matrix produced by endothelial cells in vitro: Implications for a role of heparinase-like enzymes in the neovascular response. Biochem Biophys Res Commun 142: 428-435.
2. BENITZ WE, BERNFIELD M, 1990A. Endothelial cell proteoglycans - possible mediators of vascular responses to injury. Am J Respir Cell Mol Biol 2: 407-408.
3. BENITZ WE, BERNFIELD M, 1990B. Smooth muscle cell inhibitor. US patent number 4,945,086.
4. BENITZ WE, KELLEY RT, ANDERSON CM, LORANT DE, BERNFIELD M, 1990. Endothelial heparan sulfate proteoglycan. I. Inhibitory effects on smooth muscle cell proliferation. Am J Respir Cell Mol Biol 2: 13-24.
5. BENNETT MR, SCHWARTZ SM, 1995. Antisense therapy for angioplasty restenosis: Some critical considerations. Circulation 92: 1981-1993.
6. BINGLEY JA, CAMPBELL JH, HAYWARD IP, CAMPBELL GR, 1996. Inhibition of neointimal formation by natural heparan sulfate proteoglycans of the arterial wall. Ann NY Acad Sci in press.
7. CAMPBELL JH, RENNICK RE, KALEVITCH SG, CAMPBELL GR, 1992. Heparan sulfate-degrading enzymes induce modulation of smooth muscle phenotype. Exp Cell Res 200: 156-167.
8. CASTELLOT JJ, ADDONIZIO ML, ROSENBERG R, KARNOVSKY MJ, 1981. Cultured endothelial cells produce an heparin-like inhibitor of smooth muscle cell growth. J Cell Biol 90: 372-379.
9. CASTELLOT JJ, FAVREAU LV, KARNOVSKY MJ, ROSENBERG RD, 1982. Inhibition of vascular smooth muscle cell growth by endothelial cell-derived heparin. J Biol Chem 257: 11,256-11,260.
10. CHAMLEY-CAMPBELL JH, CAMPBELL GR, 1981. What controls smooth muscle cell phenotype? Atherosclerosis 40: 347-357.
11. CLOWES AW, KARNOVSKY MJ, 1977. Suppression by heparin of smooth muscle cell proliferation in injured arteries. Nature 265: 625-626.
12. CLOWES AW, REIDY MA, CLOWES MM, 1983. Kinetics of cellular proliferation after arterial injury. Lab Invest 49: 327-333.
13. DODGE AB, LU XQ, D'AMORE PA, 1993. Density-dependent endothelial cell production of an inhibitor of smooth muscle cell growth. J Cell Biochem 53: 21-31.
14. FILLINGER MF, OCONNOR SE, WAGNER RJ, CRONENWETT JL, 1993. The effect of endothelial cell coculture on smooth muscle cell proliferation. J Vasc Surg 17: 1058-1068.
15. GOSPODAROWICZ D, LUI GM, 1981. Effect of substrata and fibroblast growth factor on the proliferation in vitro of bovine aortic endothelial cells. J Cell Physiol 109: 69-81.
16. GRAHAM LD, MITCHELL SM, UNDERWOOD PA, 1995. Inhibition of platelet heparitinase by phosphorothioate DNA oligonucleotides. Biochem Mol Biol Int 37: 239-246.
17. HAKKINEN L, OKSALA O, SALO T, RAHEMTULLA F, LARJAVA H, 1993. Immunohistochemical localisation of proteoglycans in human periodontium. J Histochem Cytochem 41: 1689-1699.
18. LAEMMLI UK, 1970. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 227: 680-685.
19. LINDBLOM A, CARLSTEDT I, FRANSSON L, 1989. Identification of the core proteins in proteoglycans synthesised by vascular endothelial cells. Biochem J 261: 145-153.
20. LINDBLOM A, LARS-AKE F, 1990. Endothelial heparan sulfate: Compositional analysis and comparison of chains from different proteoglycan populations. Glycoconjugate J 7: 545-562.
21. LINDNER V, REIDY MA, 1991. Proliferation of smooth muscle cells after vascular injury is inhibited by an antibody against basic fibroblast growth factor. Proc Natl Acad Sci USA 88: 3739-3743.
22. MACIAG T, CERUNDOLO J, ILSLEY S, KELLEY PR, FORUND R, 1979. An endothelial cell growth factor from bovine hypothalamus: Identification and partial charasterisation. Proc Natl Acad Sci USA 76: 5674-5678.
23. MORITA H, TAKEUCHI T, SUZUKI S, MAEDA K, YAMADA K, EGUCHI G, KIMATA K, 1990. Aortic endothelial cells synthesize a large chondroitin sulphate proteoglycan capable of binding to hyaluronate. Biochem J 265: 61-68.
24. NEYLON CB, LITTLE PJ, CRAGOE JR EJ, BOBIK A, 1990. Intracellular pH in human arterial smooth muscle. Circ Res 67: 814-825.
25. O'BRIEN ER, SCHWARTZ SM, 1994. Update on the biology and clinical study of restenosis. Trend Cardiovasc Med 4: 169-178.
26. OOHIRA A, WIGHT TN, BORNSTEIN P, 1983. Sulfated proteoglycans synthesised by vascular endothelial cells in culture. J Biol Chem 258: 2014-2021.
27. PEIRO C, REDONDO J, RODRIGUEZMARTINEZ MA, ANGULO J, MARIN J, SANCHEZFERRER CF, 1995. Influence of endothelium on cultured vascular smooth muscle cell proliferation. Hypertension 25: 748-751.
28. REIDY MA, 1993. Neointimal proliferation: The role of basic FGF on vascular smooth muscle cell proliferation. Thromb Haem 70: 172-176.
29. RUOSLAHTI E, PIERSCHBACHER M, ENGVALL E, 1982. Fibronectin: purification, immunochemical properties, and biological activities. Meth Enzymol 82: 803-831.
30. SCHMIDT A, SCHAFER E, BUDDECKE E, 1988. Isolation and characterisation of two proteoheparan sulfate species of calf arterial tissue. Eur J Biochem 173: 661-666.
31. SCHMIDT A, BUDDECKE E, 1990. Changes in heparan sulphate structure during transition from the proliferating to the non-dividing state of cultured arterial smooth muscle cells. Eur J Cell Biol 52: 229-235.
32. TOWBIN H, STAEHELIN T, GORDON J, 1979. Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets: procedure and some applications. Proc Natl Acad Sci USA 76: 4350-4354.
33. UNDERWOOD PA, DALTON BA, STEELE JG, BENNETT FA, STRIKE P, 1992. Anti-fibronectin antibodies which modify heparin binding and cell adhesion. J Cell Sci 102: 833-845.
34. VAN BUUL-WORTELBOER MF, BRINKMAN HJM, DINGEMANS KP, DE GROOT PG, VAN AKEN WG, VAN MOURIK JA, 1986. Reconstitution of the vascular wall in vitro. A novel model to study interactions between endothelial and smooth muscle cells. Exp Cell Res 162: 151-158.
35. WEIS JR, SUN B, RODGERS GM, 1991. Improved method of human umbilical arterial endothelial cell culture. Thromb Res 61: 171-173.
36. WEISSBERG PL, GRAINGER DJ, SHANAHAN CM, METCALFE JC, 1993. Approaches to the development of selective inhibitors of vascular smooth muscle cell proliferation. Cardiovasc Res 27: 1191-1198.
37. WHITELOCK JM, MURDOCH AD, IOZZO RV, UNDERWOOD PA, 1996. The degradation of human endothelial cell-derived perlecan and release of bound basic fibroblast growth factor by stromelysin, collagenase, plasmin and heparanases. J Biol Chem 271: 10,079-10,086.
38. WILLEMS C, ASTALDI GCB, GROOT PGD, JANSSEN MC, GONSALVEZ MD, ZEULEMAKER WP, MOURIK JAV, AKEN WGV, 1982. Media conditioned by cultured human vascular endothelial cells inhibit the growth of vascular smooth muscle cells. Exp Cell Res 139: 191-197.
39. XU CB, STAVENOW L, PESSAHRASMUSSEN H, 1993. Interactions between cultured bovine arterial endothelial and smooth muscle cells - further studies on the effects of injury and modification of the consequences of injury. Artery 20: 163-179.